LOS ANGELES--(BUSINESS WIRE)--NantOmics, a leading molecular diagnostic company and a member of the NantWorks ecosystem of companies, today announced that it has acquired the remaining shares of privately owned OncoPlex Diagnostics, an accredited clinical laboratory focused on testing tumor cell proteins using mass spectrometry analysis. Financial terms of the transaction were not disclosed.
OncoPlex was funded by Dr. Soon-Shiong's entities since 2008 and the strategic benefits of completing the acquisition include a CAP-accredited, CLIA-certified laboratory, technical expertise and a significant expansion of NantOmics’s portfolio of molecular diagnostic tests. Headquartered in Rockville, Maryland, OncoPlex provides comprehensive-profiling services of patients' tumors intended to enable more informed and better treatment decisions. The company’s proprietary quantitative proteomic clinical assays have been validated in multicenter studies and its novel multiplexed method is one of the most sensitive and specific detection tools available in the clinical laboratory today.
“OncoPlex brings to NantOmics unique, proprietary technology that provides clinically relevant and highly accurate quantitative test results for patients with cancer,” said Dr. Patrick Soon-Shiong, physician scientist, biotechnology entrepreneur and NantWorks founder. “With this integration, we have added state-of-the-art discovery tools and a complementary array of molecular diagnostic services and tests. More importantly, we have enhanced our ability to deliver patient-specific pan-omic information and, ultimately, improve disease diagnosis and therapy. We are now positioned to provide whole genomic sequencing, transcriptomics, predictive proteomics and quantitative proteomics...the most comprehensive diagnostic platform for cancer patients in the world today."
“By combining DNA sequencing, RNA sequencing and protein expression utilizing mass spectrometry, NantOmics can now offer expanded testing capabilities that provide a broader and more comprehensive picture of a patient’s unique tumor biology,” said Todd Hembrough, Ph.D., Chief Scientific Officer and formerly vice president of research and development at OncoPlex. “Moreover, NantOmics has further established itself as a leader in comprehensive molecular diagnostic testing, with the ability to provide more useful information to medical oncology professionals.”
About OncoPlex Diagnostics
OncoPlex Diagnostics is the only CAP-accredited, CLIA-certified laboratory with the unique and proprietary capability to solubilize tumor cell proteins from FFPE tissue for quantitation by mass spectrometry analysis. With next generation sequencing analysis also available from the same sample, this innovative approach allows for multiple targeted proteomic and genomic results from a biopsy specimen. For more information, please visit www.oncoplexdx.com.
About NantOmics:
NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular diagnostic capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular diagnostics company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analysing both normal and tumour cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumour sample used for genomic analysis. For more information, please visit www.nantomics.com and follow Dr. Soon-Shiong on Twitter @solvehealthcare.
